AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Other

    AICAR (100mg)

    SubcutaneouslyOnce daily100mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇺🇸 Phase II

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Research-only — no FDA/EMA approval
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Available sizes:
    100mg
    50mg

    Research monograph

    See the full AICAR encyclopedia page with mechanism, evidence tier, related variants and research context.

    Open monograph
    Free Access

    How It Works

    AICAR directly activates AMP-activated protein kinase (AMPK), increasing fatty acid oxidation, glucose uptake into muscles, mitochondrial biogenesis, and angiogenesis — processes normally activated by aerobic exercise.

    Quick Start

    • Reconstitution: Add 5.0 mL bacteriostatic water → 20 mg/mL concentration.
    • Literature-reported range: 1–3 mg once daily (gradual titration).
    • Easy measurement: At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg on a U-100 syringe.
    • Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within 28 days.
    Detailed Protocol Data

    Literature-reported ranges (5.0 mL = 20 mg/mL)

    Educational only
    Vial Size— affects syringe units
    BAC Water5 mL
    Concentration20.00 mg/mL

    Route: Subcutaneously | Frequency: Once daily

    WeekDoseUnits (per injection)
    Weeks 1–2
    1 mg
    5 Units (0.05 mL)
    Weeks 3–4
    2 mg
    10 Units (0.10 mL)
    Weeks 5–8
    3 mg
    15 Units (0.15 mL)

    Research-use literature reports subcutaneous administration once daily, increasing by 1 mg every 2 weeks. Sources vary considerably and there is no validated human dosing.

    Related compounds

    Reconstitution Steps

    1. Draw 5.0 mL of bacteriostatic water.
    2. Inject slowly down the vial wall; avoid foaming.
    3. Swirl gently until fully dissolved — do not shake.
    4. Note the reconstitution date and refrigerate at 2–8 °C.

    Protocol Overview

    • Literature-reported scope: AMPK activation, glucose and fatty-acid metabolism (mostly preclinical data).
    • Literature-described schedule: 1 → 2 → 3 mg daily over 8 weeks.

    Dosing Protocol

    • Weeks 1–2: 1 mg daily.
    • Weeks 3–4: 2 mg daily.
    • Weeks 5–8: 3 mg daily.
    • Literature-described break: 4 weeks after the cycle.
    • Break between cycles: After the 8-week cycle, the literature describes a 4-week break.

    Washout & Cycle Restart

    When can I restart?

    After the 8-week cycle, the literature describes a 4-week break.

    Minimum wait period: 4 weeks

    Storage Instructions

    • Lyophilized: −20 °C in dry, dark conditions.
    • Reconstituted: 2–8 °C; use within 28 days.
    • Avoid freeze-thaw cycles.

    Important Notes

    • WADA-banned substance.
    • For research use only.
    • May affect blood glucose.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • AMPK activation (exercise mimetic).
    • Increased fatty acid oxidation.
    • Mitochondrial biogenesis.

    Potential Side Effects:

    • Hypoglycemia (rare).
    • Gastrointestinal discomfort.

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    ❤️ Cardiovascular
    🟡 Moderate / Theoretical

    Bradycardia & hypotension

    AICAR (acadesine) caused bradycardia and hypotension in IV clinical trials. Data for subcutaneous research use is limited.

    📄 J Am Coll Cardiol 1996
    ⚠️ Other
    🟡 Moderate / Theoretical

    Uric acid increase & gout risk

    Metabolized to AMP → IMP → uric acid. Chronic use may increase serum uric acid.

    📄 Am J Physiol 1998

    References

    1. AICAR Activates AMPK in Skeletal Muscle — Cell (2008) — AICAR AMPK activation in muscle
      View Source
    2. AICAR as Exercise Mimetic in Mice — PNAS (2008) — AICAR exercise mimetic in mice
      View Source
    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    0
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇺🇸
    FDA
    Phase II

    Cardiac surgery / AMPK

    Phase II (cardioprotection)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    0 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu